Tag: Hepatitis C prevention

Does price dictate HCV drug policy?

By Amanda Fletcher

Early this year, British Columbia, Alberta, Saskatchewan, Quebec and Ontario announced the lowering of eligibility requirements for access to public coverage for life-changing hepatitis C drugs, including Epclusa, Zepatier, daclatasvir and asunaprevir. These drugs will be available to those with lower fibrosis scores for the first time (the greater the fibrosis score, the more severe the liver scarring, or cirrhosis, caused by disease.)[i]